FDA Approves Talazoparib for Metastatic Prostate Cancer FDA Approves Talazoparib for Metastatic Prostate Cancer

The oral PARP inhibitor talazoparib in combination with enzalutamide provides a new treatment option for patients with HRR gene –mutated metastatic castration-resistant prostate cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news